Can selective Bb inhibition give NovelMed Therapeutics an edge in the multibillion-dollar PNH drug market?
What the Mount Raymond acquisition means for SLAM Exploration Ltd.’s Goodwin project scale (TSXV: SXL)
Read More 6 minute read Healthcare Industry News Why Femasys’ FDA-cleared next-generation FemVue device could reshape non-radiation fertility diagnostics in the U.S. Find out how Femasys’ FDA-cleared next-generation FemVue device could reshape non-radiation fertility diagnostics and influence the U.S. women’s health market today. bySoujanya RaviDecember 18, 2025